Sonic Incytes Medical develops Velacur™, a handheld, point-of-care 3D liver health assessment solution that quantifies liver disease with technology similar to MRI elastography combined with 3D tissue sampling. Velacur is FDA-cleared, non-invasive, delivers results in about five minutes, and was launched in the U.S. market in early 2021. The device is intended to provide consistently accurate, real-time liver diagnostics in a physician’s office as an alternative to biopsy and MRI. Sonic Incytes positions the product as accessible and affordable to enable routine assessment and improved management of chronic liver disease. The company emphasizes reducing fatty liver disease and improving patient care through point-of-care ultrasound diagnostics. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes spun out of the University of British Columbia. Sonic Incytes Medical develops a portable, handheld point-of-care ultrasound solution for assessing and managing chronic liver disease, with a focus on fatty liver disease. The device uses technology similar to MRI elastography and quantifies liver disease using 3D tissue sampling to provide consistently accurate, real-time results. The company says the entire procedure takes about five minutes and offers a quick, safe, and comfortable alternative to biopsy and MRI. Sonic Incytes plans to enter the market at the end of 2020. Financially, it completed a seed financing round of over CDN$3.5 million, including a $1 million investment from Genome BC and over $2.5 million from institutional and angel investors. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes aims to commercialize its solution to improve diagnosis, treatment and management of liver disease.

Total raised

$8M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2021